Scribe Therapeutics Presents Late-Breaking Preclinical Data Supporting STX-1150, a Clinical-Stage Epigenetic Silencing Therapy Designed to Achieve Years of LDL-C Lowering After a Single Dose
Scribe Therapeutics, Inc. (Scribe), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, announced latest preclinical data from its lead cardiometabolic program STX-1150, supporting the possibility of this novel investigational therapy as an ultra-long-acting approach to LDL-C lowering that could redefine the standard of care for patients with atherosclerotic cardiovascular disease (ASCVD).
Scribe Therapeutics Achieves Regulatory Clearance to Initiate First-in-Human Clinical Study of STX-1150 for LDL-C Reduction
Scribe Therapeutics, Inc. (Scribe), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced that it has secured clearance from the Australian Therapeutic Goods Administration (TGA) to initiate a first-in-human clinical study of STX-1150 for the treatment of hypercholesterolemia, a major driver of atherosclerotic cardiovascular disease (ASCVD).
Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene Editing
Scribe Therapeutics, Inc. (Scribe), a biotechnology company engineering purpose-built CRISPR technologies to reshape the treatment of disease by enabling earlier intervention, improved outcomes, and longer, healthier lives, presented preclinical data on the latest advances across the company’s engineered CRISPR technologies at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.
Scribe Therapeutics to Highlight Engineered CRISPR Platform Advances and Lead Cardiometabolic Pipeline at ASGCT and EAS Congress 2026
Scribe Therapeutics, Inc. (Scribe), a biotechnology company engineering purpose-built CRISPR technologies designed to reshape the treatment of disease by enabling earlier intervention, improved outcomes, and longer, healthier lives, today announced its participation in the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting and the 94th European Atherosclerosis Society (EAS) Congress.
Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company
Scribe Therapeutics, Inc. (Scribe), a biotechnology company pioneering highly engineered CRISPR technologies designed to reshape the treatment of disease by enabling earlier intervention, improved outcomes, and longer, healthier lives, today announced the achievement of a second success milestone for one of the targets in its collaboration with Eli Lilly and Company (
NYSE: LLY). The companies are working towards developing in vivo CRISPR-based genetic medicines for neurological and neuromuscular disorders.
Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction
Scribe Therapeutics, Inc. (Scribe), a biotechnology company pioneering highly engineered CRISPR technologies designed to reshape the treatment of disease by enabling earlier intervention, improved outcomes, and longer, healthier lives, announced plans to enter the clinic in mid-2026 with STX-1150, its lead product candidate for the treatment of hypercholesterolemia, a major driver of atherosclerotic cardiovascular disease (ASCVD). STX-1150 is a novel liver-targeted therapy designed to epigenetically silence PCSK9 and durably reduce low-density lipoprotein cholesterol (LDL-C) without permanent DNA changes.
